Company Description
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines.
It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.
The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others.
It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence.
The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells.
The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018.
Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
| Country | United States |
| Founded | 2018 |
| IPO Date | Feb 4, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 328 |
| CEO | Dr. Steven D. Harr M.D. |
Contact Details
Address: 188 East Blaine Street, Suite 400 Seattle, Washington 98102 United States | |
| Phone | (206) 701-7914 |
| Website | sana.com |
Stock Details
| Ticker Symbol | SANA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $25.00 |
| CIK Code | 0001770121 |
| CUSIP Number | 799566104 |
| ISIN Number | US7995661045 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Steven D. Harr M.D. | President, Chief Executive Officer and Director |
| Bernard J. Cassidy J.D. | Executive Vice President, General Counsel and Corporate Secretary |
| Nathan Hardy M.B.A. | Executive Vice President and Chief Financial Officer |
| Snehal Patel | Senior Vice President and Chief Technical Officer |
| Robin Andrulevich | Executive Vice President and Chief People Officer |
| Dr. Edward Rebar Ph.D. | Head of Cell Engineering |
| Paul Brunetta M.D. | Senior Vice President and Head of Clinical and Translational Science |
| Christian Hordo M.B.A. | Executive Vice President and Chief Business Officer |
| Dr. Sonja Schrepfer M.D., Ph.D. | Senior Vice President and Head of Hypoimmune Platform |
| Dr. Terry Fry M.D. | Senior Vice President and Head of T Cell Therapeutics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 18, 2024 | 8-K | Current Report |
| Apr 3, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Mar 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Mar 1, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Feb 29, 2024 | 10-K | Annual Report |
| Feb 29, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 8, 2024 | 8-K | Current Report |